Avita Medical Inc.
RCEL · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 34.42M | 28.38M | -27.51M | -26.67M | -1.07 |
| 2023 FY | 50.14M | 42.36M | -42.66M | -35.38M | -1.40 |
| 2024 FY | 64.25M | 55.16M | -56.59M | -61.85M | -2.39 |
| 2025 FY | 71.61M | 58.82M | -42.53M | -48.59M | -1.74 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 98.26M | 13.52M | 18.16M | 918.00K | 84.74M |
| 2023 FY | 111.64M | 62.58M | 22.12M | 42.41M | 49.06M |
| 2024 FY | 79.71M | 75.21M | 14.05M | 45.99M | 4.50M |
| 2025 FY | 56.39M | 73.04M | 10.24M | 46.05M | -16.65M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -19.09M | -525.00K | -19.62M | — | -37.55M |
| 2023 FY | -38.01M | -1.45M | -39.46M | — | 3.95M |
| 2024 FY | -48.94M | -9.33M | -58.27M | — | -8.07M |
| 2025 FY | -31.20M | -1.74M | -32.93M | — | -3.81M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 165.00M | 147.76M | — | — | — |
| 2023 FY | 347.54M | 367.84M | — | — | — |
| 2024 FY | 331.30M | 363.24M | — | — | — |
| 2025 FY | 96.12M | 131.92M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 18.42M | 14.95M | -11.15M | -9.92M | -0.38 |
| 2025 Q3 | 17.06M | 13.88M | -9.15M | -13.19M | -0.46 |
| 2025 Q4 | 17.62M | 14.31M | -10.41M | -11.62M | -0.38 |
| 2026 Q1 | 19.25M | 15.73M | -8.80M | -10.61M | -34.74 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 58.13M | 71.03M | 12.22M | 44.59M | -12.89M |
| 2025 Q3 | 63.73M | 70.39M | 15.42M | 44.77M | -6.67M |
| 2025 Q4 | 56.39M | 73.04M | 10.24M | 46.05M | -16.65M |
| 2026 Q1 | 51.54M | 74.71M | 8.31M | 48.12M | -23.17M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -10.23M | -524.00K | -10.75M | — | -2.65M |
| 2025 Q3 | -5.22M | -955.00K | -6.17M | — | 3.21M |
| 2025 Q4 | -5.44M | 1.71M | -3.73M | — | -5.18M |
| 2026 Q1 | -10.07M | -22.00K | -10.09M | — | -1.93M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 139.48M | 171.86M | — | — | — |
| 2025 Q3 | 145.09M | 174.44M | — | — | — |
| 2025 Q4 | 104.83M | 140.63M | — | — | — |
| 2026 Q1 | 1.13M | 40.94M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |